Zobrazeno 1 - 4
of 4
pro vyhledávání: '"M Vatri"'
Autor:
F Verga, F Orso, C Salucci, G D‘Errico, E Perini, M Vatri, E Poletti, C Cagnoni, G Corti, M Di Bari, A Ungar, S Baldasseroni
Publikováno v:
European Heart Journal Supplements. 25:D72-D73
SGLT2–i have been shown to improve prognosis in patients with heart failure with reduced ejection fraction (HFrEF) in randomized clinical trials (RCTs). However, at the moment, we have little data on the use of these drugs in clinical practice, bot
Autor:
G D’Errico, F Orso, F Verga, C Salucci, E Perini, M Vatri, E Poletti, C Cagnoni, G Corti, M Di Bari, A Ungar, S Baldasseroni
Publikováno v:
European Heart Journal Supplements. 25:D174-D175
In July 2022 C.M., a 58–year–old woman, was admitted to our Heart Failure Outpatient Clinic. Patient with permanent AF undergoing DOAC therapy, previous double mitral and tricuspid valve replacement with bioprosthesis. As comorbidities she had st
Autor:
F Verga, F Orso, C Salucci, G D‘Errico, E Perini, M Vatri, E Poletti, C Cagnoni, G Corti, M Di Bari, A Ungar, S Baldasseroni
Publikováno v:
European Heart Journal Supplements. 25:D174-D174
Heart failure (HF), despite new therapeutic strategies, remains a condition characterized by an inauspicious prognosis and poor quality of life. The management of advanced and then terminal SC proves to be a current challenge, especially in elderly p
Autor:
C Salucci, F Orso, F Verga, G D‘Errico, E Perini, C Cagnoni, E Poletti, M Vatri, G Corti, M Di Bari, A Ungar, S Baldasseroni
Publikováno v:
European Heart Journal Supplements. 25:D174-D174
Hyperkalimia (HK) is a condition that occurs very frequently in patients with heart failure (HF). HK often limits and discourages the implementation and optimization of RAASI therapy in patients with HFrEF. The introduction of the new K–binders dru